Oropharyngeal Squamous Cell Carcinoma clinical trials

Explore recruiting oropharyngeal squamous cell carcinoma clinical trials.

Recruiting oropharyngeal squamous cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Oropharyngeal Squamous Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)

Belgium, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinoma

Austria

Human Pharmacology (Phase I)- Other EU CTIS Study details

Prospective, multicentre phase II study of de-escalation of primary chemoradiotherapy of squamous cell carcinoma of oropharynx (OPC) associated with human papilloma virus (HPV)

Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). PRIME H&N study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a therapeutic HPV DC targeting vaccine in patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (HPV.DCVax)

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Oropharyngeal Squamous Cell Carcinoma trials by city

Oropharyngeal Squamous Cell Carcinoma in Toronto Oropharyngeal Squamous Cell Carcinoma in Vancouver Oropharyngeal Squamous Cell Carcinoma in Montreal Oropharyngeal Squamous Cell Carcinoma in Calgary Oropharyngeal Squamous Cell Carcinoma in Edmonton Oropharyngeal Squamous Cell Carcinoma in Ottawa Oropharyngeal Squamous Cell Carcinoma in Winnipeg Oropharyngeal Squamous Cell Carcinoma in Quebec City Oropharyngeal Squamous Cell Carcinoma in Hamilton Oropharyngeal Squamous Cell Carcinoma in Kitchener Oropharyngeal Squamous Cell Carcinoma in London Oropharyngeal Squamous Cell Carcinoma in Halifax Oropharyngeal Squamous Cell Carcinoma in New York Oropharyngeal Squamous Cell Carcinoma in Los Angeles Oropharyngeal Squamous Cell Carcinoma in Chicago Oropharyngeal Squamous Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease